ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
9.07
-0.33 (-3.51%)
At close: May 29, 2026, 4:00 PM EDT
9.43
+0.36 (3.97%)
After-hours: May 29, 2026, 7:56 PM EDT
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, ARS Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $28.8. The average 1-year stock price forecast is 217.53% higher than the current stock price, while the lowest is $25 (+175.63%) and the highest is $32 (+252.81%).
Price Target: $28.8 (+217.53%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ARS Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 7 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $30 | Buy | Maintains | $30 | +230.76% | May 28, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 15, 2026 |
| Northland Securities | Northland Securities | Buy Maintains $25 | Buy | Maintains | $25 | +175.63% | Apr 15, 2026 |
| Roth MKM | Roth MKM | Buy Reiterates $30 | Buy | Reiterates | $30 | +230.76% | Apr 14, 2026 |
| Raymond James | Raymond James | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jan 9, 2026 |
Financial Forecast
Revenue This Year
155.58M
from 84.28M
Increased by 84.60%
Revenue Next Year
291.76M
from 155.58M
Increased by 87.53%
EPS This Year
-1.71
from -1.74
EPS Next Year
-0.79
from -1.71
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 181.8M | 343.1M | ||||||
| Avg | 155.6M | 291.8M | ||||||
| Low | 129.6M | 223.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 115.7% | 120.6% | ||||||
| Avg | 84.6% | 87.5% | ||||||
| Low | 53.8% | 43.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | -1.24 | -0.23 | |||||
| Avg | -1.71 | -0.79 | |||||
| Low | -2.01 | -1.36 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | - | - | |||||
| Avg | - | - | |||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.